Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 4 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Candesartan (CV-11974) Candesartan (CV-11974) is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
In vitro
Candesartan binds with high specificity to the angiotensin II AT1 receptors in CHO-AT1 cells with K−1 of 0.001 min−1. Candesartan does not affect cell viability or proliferation but increases the expression of VEGF and interleukin-8 in the cultured medium of KU-19-19 cells. Candesartan (0.1 nM) could reduce the maximal contractile response to angiostensin II by approximately 50%.
In vivo
Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model Candesartan (0.5 mg/kg) decreases blood pressure and inhibits AT1 binding in the subfornical organ (SFO), paraventricular nucleus of the hypothalamus (PVN), nucleus of the solitary tract (NTS) and area postrema (AP) in WKY rats. Candesartan (0.3 mg/kg) pretreatment decreases the infarct area by 31% in adult spontaneously hypertensive rats, reduces the CBF decrease at the peripheral area of ischemia and the cortical volume of severe ischemic lesion.
Cell Data
cell lines:NCI-H2228 cells
Concentrations:10 μM
Incubation Time:48 hours
Powder Purity:≥99%
| ALogP | 4.1 |
|---|
| Isomeric SMILES | CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O |
|---|---|
| Alternate CAS | 139481-59-7 |
| NSC Number | 759858 |
| MeSH Entry Terms | 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid;2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole;candesartan;CV 11974;CV-11974;CV11974 |
| Molecular Weight | 440.45 |
| Reaxy-Rn | 9232176 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9232176&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Freezing Point(°C) | 183-185°C |
|---|
| 1. Yanan Guo, Shuang Cao, Bin Geng, Juanjuan Ma, Bo Yao. (2024) Determination of sacubitril and seven sartan drugs in serum samples by online solid phase extraction-liquid chromatography-tandem mass spectrometry. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, [PMID:39603194] [10.1016/j.jpba.2024.116580] |
| 2. Liang Song, Weiwei Zheng, Shuqin Wang, Zihe Zhai, Shifen Li, Jie Ding, Liyin Shen, Jinyue Zhang, Yang Zhu, Changyou Gao. (2025) ROS-responsive core–shell microgels for phase-specific treatment of myocardial infarction via programmed drug delivery. CHEMICAL ENGINEERING JOURNAL, [PMID:] [10.1016/j.cej.2025.160295] |
| 3. Dafa Yi, Jiazong Ye, Zebei Lu, Leilei Lu, Tengfei Qi, Tong Luo, Xiuyun Peng, Abdullah Al Mamun, Quan Zhou, Daqing Chen, Shuanghu Wang. (2025) Effects of anti-hypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo. DRUG METABOLISM AND DISPOSITION, [PMID:40482432] [10.1016/j.dmd.2025.100094] |
| 4. Zhenyu Wu, Xufang Huo, Yubing Huang, Taowu Gong, Pengcheng Zhao, Yuhang Zhu, Qingfan Zeng. (2026) AngII promotes hippocampal neuron ferroptosis via inhibiting the PPARγ/ACSL3 axis leading to hypertension-related cognitive impairment. EXPERIMENTAL NEUROLOGY, [PMID:] [10.1016/j.expneurol.2026.115755] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →